Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887720 | 0.85 | CHRM2 (0.40) | ALDH1A1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5731686 | 0.85 | CHRM2 (0.40) | ALDH1A1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2887742 | 0.82 | CHRM2 (0.36) | ALDH1A1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL13791193 | 0.81 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL14417896 | 0.79 | CHRM2 (0.40) | OPRM1OPRL1ALDH1A1CHRM2CHRM4 | |
| SCHEMBL2886274 | 0.77 | — | — | |
| SCHEMBL10226445 | 0.76 | — | — | |
| SCHEMBL13803152 | 0.75 | — | — | |
| SCHEMBL12337292 | 0.75 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL26138924 | 0.75 | ATM (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202354-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | DPP4 1273/4885OPRM1 4477/4885OPRL1 4611/4885 |
| US-10202354-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | DPP4 1273/4885OPRM1 4477/4885OPRL1 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.